Nuvectis Pharma Valuation
| NVCT Stock | USD 4.95 0.14 2.91% |
At this time, the firm appears to be undervalued. Nuvectis Pharma secures a last-minute Real Value of $8.83 per share. The latest price of the firm is $4.95. Our model forecasts the value of Nuvectis Pharma from analyzing the firm fundamentals such as Current Valuation of 75.76 M, shares owned by insiders of 51.52 %, and Return On Equity of -1.4 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Nuvectis Pharma's valuation include:
Price Book 8.4555 | Enterprise Value 75.8 M | Enterprise Value Ebitda (7.38) |
Undervalued
Today
Please note that Nuvectis Pharma's price fluctuation is relatively risky at this time. Calculation of the real value of Nuvectis Pharma is based on 3 months time horizon. Increasing Nuvectis Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Nuvectis Pharma's intrinsic value may or may not be the same as its current market price of 4.95, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.95 | Real 8.83 | Target 20.67 | Hype 4.95 | Naive 6.35 |
The intrinsic value of Nuvectis Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Nuvectis Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Nuvectis Pharma helps investors to forecast how Nuvectis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Nuvectis Pharma more accurately as focusing exclusively on Nuvectis Pharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Nuvectis Pharma's intrinsic value based on its ongoing forecasts of Nuvectis Pharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Nuvectis Pharma's closest peers.
Nuvectis Pharma Cash |
|
Nuvectis Valuation Trend
Nuvectis Pharma's real value is important for investors to make better decisions and a more accurate overall view of Nuvectis Pharma's financial worth over time. Using both Nuvectis Pharma's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Nuvectis Pharma Total Value Analysis
Nuvectis Pharma is now forecasted to have valuation of 75.76 M with market capitalization of 95.64 M, debt of 6.98 M, and cash on hands of 13.57 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Nuvectis Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
75.76 M | 95.64 M | 6.98 M | 13.57 M |
Nuvectis Pharma Asset Utilization
One of the ways to look at asset utilization of Nuvectis is to check how much profit was generated for every dollar of assets it reports. Nuvectis Pharma secures a negative usage of assets of -0.61 %, losing $0.006086 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Nuvectis Pharma shows how discouraging it operates for each dollar spent on its assets.Nuvectis Pharma Ownership Allocation
Nuvectis Pharma maintains a total of 19.32 Million outstanding shares. Nuvectis Pharma holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Nuvectis Pharma Profitability Analysis
Net Loss for the year was (22.26 M) with profit before overhead, payroll, taxes, and interest of 0.About Nuvectis Pharma Valuation
The stock valuation mechanism determines Nuvectis Pharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Nuvectis Pharma based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Nuvectis Pharma. We calculate exposure to Nuvectis Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Nuvectis Pharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -22.9 M | -24 M | |
| Pretax Profit Margin | (115.28) | (121.04) | |
| Operating Profit Margin | (116.18) | (121.99) | |
| Net Loss | (113.48) | (119.15) | |
| Gross Profit Margin | (115.28) | (121.04) |
Nuvectis Pharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Nuvectis Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 15.6 M |
Nuvectis Pharma Current Valuation Indicators
Nuvectis Pharma's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Nuvectis Pharma's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Nuvectis Pharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Nuvectis Pharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Nuvectis Pharma's worth.Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.